Sequence 1 from Patent US 20070293424

General Information


DRACP ID  DRACP01302

Peptide Name   Sequence 1 from Patent US 20070293424

Sequence  HGVSGWGQHGTHG

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antimicrobial, Antitumor, Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01302

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C56H77N21O17

Absent amino acids  ACDEFIKLMNPRY

Common amino acids  G

Mass  153059

Pl  7.81

Basic residues  3

Acidic residues  0

Hydrophobic residues  2

Net charge  3

Boman Index  -1442

Hydrophobicity  -102.31

Aliphatic Index  22.31

Half Life 
  Mammalian: 3.5 hour
  Yeast: 10 min
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  458.33

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2007/0293424 A1

Patent Title  Antitumoral and Antiviral Peptides.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status: Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013

Other Published ID  EP1705182A1  EP1705182A4  EP1705182B1  US8372406  WO2005068491A1 




DRACP is developed by Dr.Zheng's team.